Taptiqom sine (Taptiqom) Augndropar, lausn 15 microg/ml + 5 mg/ml Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

taptiqom sine (taptiqom) augndropar, lausn 15 microg/ml + 5 mg/ml

santen oy* - tafluprostum inn; timololum maleat - augndropar, lausn - 15 microg/ml + 5 mg/ml

Balance Kviðskilunarlausn 1,5 % Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

balance kviðskilunarlausn 1,5 %

fresenius medical care deutschland gmbh - natrii chloridum; calcii chloridum; magnesii chloridum; glucosum; natrii lactas - kviðskilunarlausn - 1,5 %

Balance Kviðskilunarlausn 2,3 % Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

balance kviðskilunarlausn 2,3 %

fresenius medical care deutschland gmbh - natrii chloridum; calcii chloridum; magnesii chloridum; glucosum; natrii lactas - kviðskilunarlausn - 2,3 %

Balance Kviðskilunarlausn 4,25 % Islàndia - islandès - LYFJASTOFNUN (Icelandic Medicines Agency)

balance kviðskilunarlausn 4,25 %

fresenius medical care deutschland gmbh - natrii chloridum; calcii chloridum; magnesii chloridum; glucosum; natrii lactas - kviðskilunarlausn - 4,25 %

Vectra Felis Unió Europea - islandès - EMA (European Medicines Agency)

vectra felis

ceva santé animale - pyriproxyfen, dinotefuran - sníklaeyðandi vörur, skordýraeitur og repellents, Önnur ectoparasiticides fyrir baugi nota, pyriproxyfen, sturtu - kettir - meðferð og koma í veg fyrir fló sníkjudýra (ctenocephalides sus) á ketti. einn umsókn í veg fyrir fló árás í einn mánuð. Það kemur í veg fyrir einnig fjölgun flær af því að hamla fló tilkomu í umhverfið köttur í 3 mánuði.

Isemid Unió Europea - islandès - EMA (European Medicines Agency)

isemid

ceva santé animale - gi - hár-loft þvagræsilyf, súlfónamíð, látlaus - hundar - fyrir meðferð klínískum merki tengjast hjartabilun í hunda, þar á meðal í lungum bjúg.

Tulaven Unió Europea - islandès - EMA (European Medicines Agency)

tulaven

ceva santé animale - túlatrómýsín - sýklalyf til almennrar notkunar - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilvist sjúkdómsins í hjörðinni skal komið á áður en meðferð með bráðaofnæmi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilvist sjúkdómsins í hjörðinni skal komið á áður en meðferð með bráðaofnæmi. the product should only be used if pigs are expected to develop the disease within 2–3 days. sauðfé: meðferð á fyrstu stigum smitandi beinbólgu (fótspyrnu) í tengslum við veirufræðilega dichelobacter nodosus sem krefst kerfisbundinnar meðferðar.

Coxevac Unió Europea - islandès - EMA (European Medicines Agency)

coxevac

ceva santé animale - óvirkt coxiella burnetii bóluefni, stofn nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.